#Monit gtn 2.6mg Patch#
#Monit gtn 2.6mg code#
#Monit gtn 2.6mg free#

Glyceryl trinitrate 400micrograms/dose pump sublingual spray Glyceryl trinitrate 500microgram sublingual tablets (A A H Pharmaceuticals Ltd)Įumon xl 40mg Tablet (Neo Laboratories Ltd) Minitran 15 transdermal patches (Meda Pharmaceuticals Ltd) Minitran 10 transdermal patches (Meda Pharmaceuticals Ltd)

#Monit gtn 2.6mg free#

Nitrolingual 400microgram/dose Pump spray cfc free (Lipha Pharmaceuticals Ltd) Suscard Buccal 3mg tablets (Forest Laboratories UK Ltd) Monit xl 60 60mg Modified-release tablet (Sterwin Medicines) Imazin XL tablets (Napp Pharmaceuticals Ltd) Sustac 10mg modified-release tablets (Forest Laboratories UK Ltd) Mycardol 30mg Tablet (Sanofi-Synthelabo Ltd)Ĭardiacap 30mg Capsule (Consolidated Chemicals (UK) Ltd) Isosorbide dinitrate 1.25mg/dose sublingual spray sugar free Suscard Buccal 5mg tablets (Forest Laboratories UK Ltd) MCR-50 modified-release capsules (Pfizer Ltd) Vascardin 10mg Tablet (Nicholas Laboratories Ltd)Ĭoro-nitro 400microgram/dose Spray (Roche Products Ltd) Isordil Tembids 40mg modified-release capsules (Shire Pharmaceuticals Ltd) Sorbitrate 20mg Tablet (AstraZeneca UK Ltd) Isosorbide dinitrate 25mg/50ml infusion bottles Suscard Buccal 2mg tablets (Forest Laboratories UK Ltd) Isosorbide dinitrate 100mg/100ml solution for infusion bottles Glyceryl trinitrate 400microgram/dose Spray Isosorbide mononitrate 50mg modified-release tablets Xismox XL 60 tablets (Thornton & Ross Ltd) Glyceryl trinitrate 15mg/24hours transdermal patches Glyceryl trinitrate 500microgram sublingual tablets

#Monit gtn 2.6mg Patch#

Glyceryl trinitrate 2.5mg/24hr transdermal patch Isordil 30mg tablets (Shire Pharmaceuticals Ltd) Isordil 5mg tablets (Shire Pharmaceuticals Ltd) Trangina XL 60mg tablets (Actavis UK Ltd)

#Monit gtn 2.6mg code#

The HbA1C variability-HH association was stronger in more recent years in T2D (P≤0.004).Ĭonclusions: HbA1C variability is a strong predictor for HH in T1D and T2D.Īuthor for correspondence Elizabeth J Mayer-Davis Email for correspondence Code list: res50: nitrates 285 codes in list Code In T2D for first HH, the association was the strongest in non-insulin non-sulfonylurea users (P<0.0001) for recurrent HH, the association was stronger in insulin users than sulfonylurea users (P=0.07). In T2D, a 1.0% increase in HbA1C variability was associated with 556% higher first HH risk (95% CI, 3.88-11.08) and 573% higher recurrent HH risk (95% CI, 1.59-28.51). Results: In T1D, every 1.0% increase in HbA1C variability was associated with 90% higher first HH risk (95% CI, 1.25-2.89) and 392% higher recurrent HH risk (95% CI, 1.17- 20.61). Conditional logistic models were applied to determine association of HbA1C variability with first and recurrent HH. HbA1C variability was determined by standard deviation of ≥3 HbA1C results. Methods: Using nested case-control design in electronic health record data in England, one case with first or recurrent HH was matched to one control who had not experienced HH in incident T1D and T2D adults. Link to article Abstract Aims: To determine association between HbA1C variability and hypoglycemia requiring hospitalization (HH) in adults with type 1 diabetes (T1D) and type 2 diabetes (T2D).